CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)

N/A

Report date: 2023/05/05 17:35:15

Base Information

Drug NameCD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-PD-1Anti-CD19 +[4] 
TargetsProgrammed cell death protein 1B-lymphocyte antigen CD19T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSecond Affiliated Hospital Of Zhejiang University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Zhejiang University School Of MedicineSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A